Literature DB >> 27624807

An Irish outbreak of New Delhi metallo-β-lactamase (NDM)-1 carbapenemase-producing Enterobacteriaceae: increasing but unrecognized prevalence.

C O'Connor1, M Cormican2, T W Boo2, E McGrath3, B Slevin4, A O'Gorman4, M Commane4, S Mahony5, E O'Donovan4, J Powell6, R Monahan6, C Finnegan6, M G Kiernan5, J C Coffey5, L Power6, N H O'Connell1, C P Dunne7.   

Abstract

BACKGROUND: Carbapenemase-producing Enterobacteriaceae (CPE) may cause healthcare-associated infections with high mortality rates. New Delhi metallo-β-lactamase-1 (NDM-1) is among the most recently discovered carbapenemases. AIM: To report the first outbreak of NDM-1 CPE in Ireland, including microbiological and epidemiological characteristics, and assessing the impact of infection prevention and control measures.
METHODS: This was a retrospective microbiological and epidemiological review. Cases were defined as patients with a CPE-positive culture. Contacts were designated as roommates or ward mates.
FINDINGS: This outbreak involved 10 patients with a median age of 71 years (range: 45-90), located in three separate but affiliated healthcare facilities. One patient was infected (the index case); the nine others were colonized. Nine NDM-1-producing Klebsiella pneumoniae, an NDM-1-producing Escherichia coli and a K. pneumoniae carbapenemase (KPC)-producing Enterobacter cloacae were detected between week 24, 2014 and week 37, 2014. Pulsed-field gel electrophoresis demonstrated similarity. NDM-1-positive isolates were meropenem resistant with minimum inhibitory concentrations (MICs) ranging from 12 to 32 μg/mL. All were tigecycline susceptible (MICs ≤1 μg/mL). One isolate was colistin resistant (MIC 4.0 μg/mL; mcr-1 gene not detected). In 2015, four further NDM-1 isolates were detected.
CONCLUSION: The successful management of this outbreak was achieved via the prompt implementation of enhanced infection prevention and control practices to prevent transmission. These patients did not have a history of travel outside of Ireland, but several had frequent hospitalizations in Ireland, raising concerns regarding the possibility of increasing but unrecognized prevalence of NDM-1 and potential decline in value of travel history as a marker of colonization risk. Copyright Â
© 2016 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Carbapenemase-producing Enterobacteriaceae; Ireland; Multidrug-resistant organism; New Delhi metallo-β-lactamase-1 (NDM-1); Outbreak

Mesh:

Substances:

Year:  2016        PMID: 27624807     DOI: 10.1016/j.jhin.2016.08.005

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  12 in total

1.  A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.

Authors:  Karlijn van Loon; Anne F Voor In 't Holt; Margreet C Vos
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 2.  NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.

Authors:  Wenjing Wu; Yu Feng; Guangmin Tang; Fu Qiao; Alan McNally; Zhiyong Zong
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

3.  Anti-microbial coating innovations to prevent infectious diseases (AMiCI): Cost action ca15114.

Authors:  Colum P Dunne; Minna M Keinänen-Toivola; Anne Kahru; Birgit Teunissen; Hulya Olmez; Isabel Gouveia; Luis Melo; Kazimierz Murzyn; Martina Modic; Merja Ahonen; Pete Askew; Theofilos Papadopoulos; Christian Adlhart; Francy R L Crijns
Journal:  Bioengineered       Date:  2017-05-19       Impact factor: 3.269

4.  Indistinguishable NDM-producing Escherichia coli isolated from recreational waters, sewage, and a clinical specimen in Ireland, 2016 to 2017.

Authors:  Bláthnaid M Mahon; Carina Brehony; Elaine McGrath; James Killeen; Martin Cormican; Paul Hickey; Shane Keane; Belinda Hanahoe; Ann Dolan; Dearbháile Morris
Journal:  Euro Surveill       Date:  2017-04-13

Review 5.  Antibiotic use for acute respiratory tract infections (ARTI) in primary care; what factors affect prescribing and why is it important? A narrative review.

Authors:  Ray O'Connor; Jane O'Doherty; Andrew O'Regan; Colum Dunne
Journal:  Ir J Med Sci       Date:  2018-03-12       Impact factor: 1.568

6.  Medical management of acute upper respiratory infections in an urban primary care out-of-hours facility: cross-sectional study of patient presentations and expectations.

Authors:  Raymond O'Connor; Jane O'Doherty; Andrew O'Regan; Aoife O'Neill; Claire McMahon; Colum P Dunne
Journal:  BMJ Open       Date:  2019-02-15       Impact factor: 2.692

7.  Reflections on a national public health emergency response to carbapenemase-producing Enterobacterales (CPE).

Authors:  Hilary Humphreys; Martin Cormican; Wendy Brennan; Karen Burns; Diarmuid O'Donovan; Therese Dalchan; Shirley Keane; Anne Sheahan
Journal:  Epidemiol Infect       Date:  2022-03-18       Impact factor: 2.451

8.  What are acute NHS trusts in England doing to prevent the cross-border spread of carbapenem-resistant Enterobacteriaceae?

Authors:  Sharon Mawdsley
Journal:  J Infect Prev       Date:  2020-07-21

9.  Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control.

Authors:  A P Magiorakos; K Burns; J Rodríguez Baño; M Borg; G Daikos; U Dumpis; J C Lucet; M L Moro; E Tacconelli; G Skov Simonsen; E Szilágyi; A Voss; J T Weber
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-15       Impact factor: 4.887

10.  Management of Staphylococcus aureus bacteraemia (SAB) in the oncology patient: Further evidence supports prompt removal of central venous catheters and shorter duration of intravenous antimicrobial therapy.

Authors:  Colum P Dunne; Phelim Ryan; Roisin Connolly; Suzanne S Dunne; Mohammed A Kaballo; James Powell; Bernie Woulfe; Nuala H O'Connell; Rajnish K Gupta
Journal:  Infect Prev Pract       Date:  2020-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.